ECMO - Extracorporeal Membrane Oxygenation Anticoagulation and Hemostasis Questions and Answers — Questions and Answers
Question 1: A patient on VA ECMO is managed with a continuous unfractionated heparin (UFH) infusion. The primary laboratory test that directly measures the functional effect of UFH by quantifying its inhibition of a specific clotting factor is the:
- Activated Clotting Time (ACT)
- Prothrombin Time (PT/INR)
- Anti-Factor Xa assay (Correct answer)
- Activated Partial Thromboplastin Time (aPTT)
Correct answer: Anti-Factor Xa assay
The Anti-Factor Xa assay directly measures the ability of heparin-bound antithrombin to inhibit Factor Xa, providing a specific quantification of the drug's effect. While aPTT and ACT are also used to monitor UFH, they are global tests of the intrinsic pathway and can be affected by many other clinical variables, making them less specific than the Anti-Xa assay.
Question 2: A 48-year-old patient on VV ECMO for ARDS for the past week develops a sudden drop in platelet count from 160,000/µL to 55,000/µL. Simultaneously, new thrombus is visualized in the oxygenator. This clinical presentation is most suspicious for which of the following complications?
- Hemodilution from fluid overload
- Heparin-Induced Thrombocytopenia (HIT) (Correct answer)
- Disseminated Intravascular Coagulation (DIC)
- Sepsis-induced thrombocytopenia
Correct answer: Heparin-Induced Thrombocytopenia (HIT)
The classic presentation of Heparin-Induced Thrombocytopenia (HIT) involves a significant drop in platelet count (typically >50%) occurring 5-10 days after heparin exposure, combined with a paradoxical prothrombotic state leading to new or worsening thrombosis. While DIC and sepsis can cause thrombocytopenia, the combination with a new thrombotic event strongly points towards HIT.
Question 3: A patient on ECMO develops significant bleeding from the cannulation site. Laboratory results show an aPTT of 120 seconds (goal 60-80s), hemoglobin of 7.0 g/dL, and platelets of 50,000/µL. Which of the following represents the most appropriate sequence of initial interventions?
- Increase ECMO blood flow and administer protamine sulfate.
- Administer fresh frozen plasma (FFP) and request a surgical consult.
- Administer protamine sulfate and then transfuse platelets.
- Stop the heparin infusion, transfuse packed red blood cells and platelets. (Correct answer)
Correct answer: Stop the heparin infusion, transfuse packed red blood cells and platelets.
The patient is actively bleeding with a supratherapeutic aPTT, anemia, and thrombocytopenia. The immediate priorities are to remove the offending agent (stop the heparin), correct the anemia (transfuse PRBCs), and improve platelet count to aid hemostasis. FFP or protamine may be considered, but stopping the heparin and repleting blood components are the critical first steps.
Question 4: Unfractionated heparin achieves its anticoagulant effect in the ECMO circuit primarily through which mechanism of action?
- Directly binding to and inhibiting thrombin (Factor IIa).
- Chelating calcium ions, which are essential for the coagulation cascade.
- Preventing the aggregation of platelets on the circuit surface.
- Binding to antithrombin, greatly accelerating its inactivation of thrombin and Factor Xa. (Correct answer)
Correct answer: Binding to antithrombin, greatly accelerating its inactivation of thrombin and Factor Xa.
Unfractionated heparin is an indirect anticoagulant. It works by binding to the endogenous anticoagulant antithrombin. This binding causes a conformational change in antithrombin, increasing its activity by over 1000-fold, leading to the rapid inactivation of key clotting factors, primarily thrombin (Factor IIa) and Factor Xa.
Question 5: Which of the following is a direct thrombin inhibitor commonly used as an alternative anticoagulant for patients on ECMO who have confirmed Heparin-Induced Thrombocytopenia (HIT)?
- Bivalirudin (Correct answer)
- Warfarin
- Fondaparinux
- Clopidogrel
Correct answer: Bivalirudin
Bivalirudin is a direct thrombin inhibitor (DTI) that is frequently used as a first-line alternative to heparin in patients with HIT. It directly binds to thrombin to prevent fibrin formation and does not require antithrombin for its effect. Warfarin is an oral medication unsuitable for acute ECMO. Fondaparinux is a Factor Xa inhibitor and clopidogrel is an antiplatelet agent.
Question 6: Beyond the effects of administered anticoagulants, a significant contributor to the acquired coagulopathy in patients on ECMO is:
- A deficiency of Vitamin K due to poor nutrition.
- Hypothermia from the heat exchanger impairing clotting factor function.
- Continuous platelet activation and consumption due to shear stress and contact with circuit surfaces. (Correct answer)
- An increase in circulating antithrombin produced in response to inflammation.
Correct answer: Continuous platelet activation and consumption due to shear stress and contact with circuit surfaces.
The ECMO circuit itself induces a complex coagulopathy. The non-biologic surfaces and the high shear forces, particularly from the pump, cause continuous contact activation of the coagulation cascade and lead to platelet activation, consumption, and dysfunction. This state of 'consumptive coagulopathy' contributes significantly to both bleeding and thrombotic risks, independent of heparin therapy.
ECMO - Extracorporeal Membrane Oxygenation Anticoagulation and Hemostasis Questions and Answers
A patient on VA ECMO is managed with a continuous unfractionated heparin (UFH) infusion.
The primary laboratory test that directly measures the functional effect of UFH by quantifying its inhibition of a specific clotting factor is the: